FDA Announces Moves to Fast-Track Psychedelic Therapies
FDA is announcing several actions aimed at accelerating the development of treatments for serious mental illness, following a recent executive order from president Trump that directed federal health agencies to expand access to emerging therapies. The measures include new priority review incentives, clearance of early-stage clinical research, and forthcoming regulatory guidance focused on a controversial but increasingly studied class of drugs — psychedelic compounds that act on serotonin-2A receptors.
The push stems from a 4/18 White House directive HHS to speed the development of treatments for conditions such as treatment-resistant depression, post-traumatic stress disorder, and substance use disorders.
HHS secretary Robert F. Kennedy Jr. said the administration is prioritizing therapies that show early promise. “We are accelerating the research, approval, and responsible access to promising mental health treatments — including psychedelic therapies like ibogaine,” he said, adding that FDA will emphasize drugs granted a breakthrough therapy designation.
FDA commissioner Marty Makary emphasized that while the agency is moving quickly, it will maintain strict scientific standards. He pointed to the potential of these treatments to address “the nation’s mental health crisis,” particularly among veterans, while stressing the need for rigorous clinical evidence.
Priority vouchers and new trials
As part of the initiative, the FDA is issuing national priority vouchers to three companies developing:
- Psilocybin-based therapies for treatment-resistant depression
- Psilocybin for major depressive disorder
- Methylone for post-traumatic stress disorder
The agency also cleared an investigational new drug (IND) application for noribogaine hydrochloride, allowing a Phase 1 clinical trial to proceed in the U.S. The compound is a derivative of ibogaine, a psychoactive substance derived from the African shrub Tabernanthe iboga, and is being studied as a potential treatment for alcohol use disorder.
The sponsor, developing the drug candidate DemeRx NB, will evaluate noribogaine in a controlled clinical setting. FDA noted that allowing the study to proceed does not indicate the drug is safe or effective, and that it will continue reviewing data as it emerges.
The agency also said it plans to release final guidance “imminently” to help drug developers navigate the unique challenges of studying psychedelic compounds, which can produce profound perceptual and psychological effects that complicate traditional clinical trial designs. The guidance is expected to outline recommendations on study design, patient monitoring, and data collection to ensure trials meet regulatory standards.
While advocates see the move as a long-overdue response to unmet mental health needs, the agency underscored that all therapies will still be subject to standard approval requirements, including well-controlled clinical trials demonstrating safety and efficacy.